Search Results
Jun 03, 2026, 12:04 ET RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
(remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034))Improved median time to viral RNA clearance by ≥4 days in opaganib-treated patients (median 10 days vs. not reached by Day 14 in placebo, HR 1.34, p=0.043)Demonstrated
More news about: RedHill Biopharma Ltd.
Jun 03, 2026, 08:04 ET TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
cancers using next-generation RNA therapeutics.BOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk
More news about: TransCode Therapeutics, Inc.
Jun 03, 2026, 07:00 ET Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases
heterogeneous mutations, that are not addressable with existing technologies. By rewriting RNA using the cell's natural RNA splicing machinery — without modifying the genome or introducing foreign enzymes — Ascidian's RNA exon editors are designed to combine the durability of gene therapy while sharply reducing
More news about: Ascidian Therapeutics
Jun 02, 2026, 14:44 ET Zymo Research Introduces Zymo Services: An Integrated Portfolio Extension Built for High-Impact Scientific Partnership
first-time incentives for microbiome sequencing and RNA-Seq projects; and a referral program that rewards existing customers for connecting colleagues with Zymo's services expertise. Zymo Services will also
More news about: Zymo Research Corp.
Jun 02, 2026, 11:32 ET MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
collection workflows for circulating tumor DNA (ctDNA) plasma in Streck Cell-Free DNA BCT and EDTA tubes, double-spun plasma for cell-free DNA and cell-free RNA applications, plasma for circulating tumor cell (CTC) enrichment, serum for protein biomarker discovery, and PBMCs and buffy coat for genomic baseline
More news about: MT Group
Jun 02, 2026, 09:00 ET Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
(remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median time to viral RNA clearance by ≥4 days in opaganib-treated patients (median 10 days vs. not reached by Day 14 in placebo, HR 1.34, p=0.043) Demonstrated
More news about: RedHill Biopharma Ltd.
Jun 02, 2026, 04:19 ET Skyhawk Therapeutics gibt Zwölfmonats-Zwischenergebnisse der klinischen Phase-1/2-Studie zu SKY-0515 bei der Huntington-Krankheit bekannt
der Fähigkeit, das RNA-Spleißen mit einem kleinen Molekül zu modulieren, und bieten Patienten weltweit eine Therapie", sagte Dr. Phillip Sharp, Gründungsmitglied des wissenschaftlichen Beirats von Skyhawk und Nobelpreisträger für seine bahnbrechende Arbeit zum RNA-Spleißen. „Die RNA-Revolution schreitet
More news about: Skyhawk Therapeutics
Jun 01, 2026, 12:00 ET Eclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution
eSENSE Break™ uses next-generation sequencing to map RNA fragmentation sites at single-nucleotide resolution across linear mRNA, self-amplifying RNA, and circular RNA therapeutics.For linear mRNA, eSENSE Break pinpoints fragmentation hotspots across the sequence,
More news about: Eclipsebio
Jun 01, 2026, 08:11 ET Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years
can become resistant to immunotherapy. For this reason, researchers have looked at adding vaccines.The vaccine intismeran is based on messenger RNA, a chemical cousin of DNA that provides cells with instructions for making proteins. Intismeran and other mRNA cancer vaccines are meant to teach the
More news about: NYU Langone Health System
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
power of the ability to modulate RNA splicing with a small molecule, offering a therapy to patients worldwide," said Phillip Sharp, PhD, Founding Member of Skyhawk's Scientific Advisory Board and Nobel Prize Laureate for his groundbreaking work on RNA splicing. "The RNA revolution continues and I couldn't
More news about: Skyhawk Therapeutics
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
power of the ability to modulate RNA splicing with a small molecule, offering a therapy to patients worldwide," said Phillip Sharp, PhD, Founding Member of Skyhawk's Scientific Advisory Board and Nobel Prize Laureate for his groundbreaking work on RNA splicing. "The RNA revolution continues and I couldn't
More news about: Skyhawk Therapeutics
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
cell surface transmembrane protein involved in neuronal development that is primarily expressed in central nervous system (CNS) tissues. A large-scale RNA analysis demonstrated that SEZ6 is highly expressed across SCLC and other tumors of neuroendocrine origin. In SCLC, expression exceeds other approved
More news about: Whitehawk Therapeutics, Inc.
May 28, 2026, 12:59 ET Ribo kündigt Einreichung eines Antrags auf eine klinische Phase-2-Studie bei der EMA an und treibt damit die Entwicklung von siRNA-Therapeutika zur Behandlung thromboembolischer Erkrankungen weiter voran
siRNA-Programme in Europa in die nächste Phase der klinischen Entwicklung zu führen. Dieser Meilenstein spiegelt unser Engagement wider, das volle Potenzial RNA-basierter Therapien auszuschöpfen, um Patienten, die derzeit nicht angemessen behandelt werden, Antikoagulanzien mit einem verbesserten Nutzen-Risiko-Profil
More news about: Suzhou Ribo Life Science Co., Ltd.
May 27, 2026, 22:51 ET Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects our commitment to unlocking the full potential of RNA-based therapies to provide anticoagulant options with improved benefit-risk profile for patients not being adequately treated today." says Dr. Anders
More news about: Suzhou Ribo Life Science Co., Ltd.
May 27, 2026, 13:12 ET Uncommon Productions Wins Five Telly Awards for 'Cracking the Code: Phil Sharp and the Biotech Revolution'
Cracking the Code: Phil Sharp and the Biotech Revolution chronicles the life and groundbreaking work of Nobel laureate Phil Sharp, whose discoveries in RNA splicing helped launch the biotech revolution. The documentary explores how fundamental science, when paired with perseverance and imagination, can transform
More news about: Uncommon Productions
May 27, 2026, 08:04 ET TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode's
More news about: TransCode Therapeutics, Inc.
May 27, 2026, 08:00 ET Living bandage accelerates healing across multiple wound types
healing response."At the cellular level, the engineered cells demonstrated activation of key wound-healing pathways, which was validated through RNA sequencing. Transcriptomic analysis revealed coordinated upregulation of genes associated with tissue regeneration and immune modulation, providing a
More news about: Rice University
May 27, 2026, 07:36 ET American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing
DNA markers and hemoglobin.A mt-sRNA test (brand name ColoSense) is a new at-home multi-target test that analyzes stool samples for specific RNA markers and hemoglobin.These tests demonstrate high sensitivity for colorectal cancer and moderate sensitivity for advanced precancerous
More news about: American Cancer Society
May 27, 2026, 07:00 ET Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
Designation.About ElebsiranElebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is
More news about: Brii Biosciences Limited
May 27, 2026, 03:00 ET ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)
therapy designed to inhibit miR-23b to address the underlying RNA-driven pathology of DM1. A second presentation highlights the dual mechanism of action of ATX-01, including upregulation of MBNL protein expression and reduction of toxic DMPK RNA, leading to improved splicing regulation. A third presentation
More news about: ARTHEx Biotech
May 26, 2026, 10:50 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
was the percent change from baseline in fasting triglycerides at six months compared to placebo.About olezarsen Olezarsen is an RNA-targeted medicine being evaluated for the treatment of severe hypertriglyceridemia. Olezarsen is designed to lower the body's production of apoC-III,
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 10:46 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
change from baseline in fasting triglycerides at six months compared to placebo.About olezarsen Olezarsen is an RNA-targeted medicine being evaluated for the treatment of severe hypertriglyceridemia. Olezarsen is designed to lower the body's production of apoC-III,
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 09:00 ET Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery
In this episode, Lexogen's CEO shares his perspective on the growing role of RNA sequencing and transcriptomics in enabling AI-driven drug discovery. The discussion highlights how high-quality, dedicated data built with AI training
More news about: LEXOGEN